ArticleJournal of inflammation research2025
Transcriptome Combined with Mendelian Randomization to Identify and Validate Biomarkers Associated with Parthanatos in Sepsis.
Article in Journal of inflammation research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: Sepsis, which is triggered by infection and characterized by a systemic inflammatory response, has been associated with the diagnosis of sepsis, although the detailed molecular basis remains unclear. This study explores parthanatos-related genes (PRGs) as potential biomarkers for sepsis diagnosis and treatment. Patients and Methods: Data from GSE65682, GSE167363, and GSE95233 were analyzed. PRGs were identified, and candidate genes were selected by intersecting differentially expressed genes (DEGs) with key PRG-associated module genes. Biomarkers were determined through Mendelian randomization (MR), machine learning, Receiver Operating Characteristic (ROC) analysis, and validation. A nomogram was constructed. Additional analyses included immune cell infiltration, Gene Set Enrichment Analysis (GSEA), molecular networks, and drug predictions. Single-cell analysis of biomarkers was performed in GSE167363. Biomarker expression was validated using Real-Time Quantitative Polymerase Chain Reaction (RT-qPCR). Results: BRD1 and FOXJ3 were identified as biomarkers for sepsis. The nomogram based on these biomarkers showed strong predictive power. Immune infiltration analysis revealed that Macrophages M0 negatively correlated with both BRD1 and FOXJ3. A lncRNA-miRNA-mRNA network involving 26 miRNAs and 299 lncRNAs was predicted. GSEA showed associations with extracellular matrix organization, keratinization, and mRNA splicing. Drug prediction indicated digoxin, doxorubicin, and daunorubicin could target BRD1 and FOXJ3. The single-cell analysis results showed a significant differential expression of the FOXJ3 gene between spermatogenic cells. RT-qPCR confirmed that BRD1 was significantly decreased in sepsis, while FOXJ3 showed no significant difference. Conclusion: BRD1 and FOXJ3 were identified as sepsis biomarkers, offering new insights into sepsis pathogenesis and potential clinical applications for diagnosis and treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.